12645 MEMORIAL DR., SUITE F1 #305, HOUSTON, TX
Other Events
Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Amended material disclosure
Coya Therapeutics Elects Wilbur Ross and Dieter Weinand as Class I Directors
Annual Report to Security Holders
Coya Therapeutics Enters $30 Million Sales Agreement with Leerink Partners
Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload